Human kallikrein 8 protein is a favorable prognostic marker in ovarian cancer

Clinical Cancer Research

Volumn 12, Issue 5, 2006, Pages 1487-1493

  Borgoño, Carla A ^a,b   Kishi, Tadaaki ^a,b   Scorilas, Andreas ^c   Harbeck, Nadia ^d   Dorn, Julia ^d   Schmalfeldt, Barbara ^d   Schmitt, Manfred ^d   Diamandis, Eleftherios P ^a,b  

^a MOUNT SINAI HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF ATHENS   (Greece)

^d TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CA 125 ANTIGEN; MESSENGER RNA; NEUROPSIN;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITHELIUM TUMOR; FEMALE; GYNECOLOGIC CANCER; HISTOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS; PROTEIN LOCALIZATION; TUMOR VOLUME;

ADENOCARCINOMA, CLEAR CELL; ADENOCARCINOMA, MUCINOUS; ADULT; AGED; AGED, 80 AND OVER; CA-125 ANTIGEN; CARCINOMA, ENDOMETRIOID; CYSTADENOCARCINOMA, SEROUS; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KALLIKREINS; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; PROGNOSIS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 33645094382     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-2106     Document Type: Article

References (52)

1. Jemal A, Murray T, Ward E, et al. Cancer statistics. CA Cancer J Clin 2005;55:10-30.
2. Schink JC. Current initial therapy of stage III and IV ovarian cancer: challenges for managed care. Semin Oncol 1999;26:2-7.
3. Cannistra SA. Cancer of the ovary. N Engl J Med 2004;351:2519-29.
4. Bandera CA, Ye B, Mok SC. New technologies for the identification of markers for early detection of ovarian cancer. Curr Opin Obstet Gynecol 2003;15:51-5.
5. Dogan E, Saygili U, Tuna B, et al. p53 and mdm2 as prognostic indicators in patients with epithelial ovarian cancer: a multivariate analysis. Gynecol Oncol 2005;97:46-52.
6. Konecny G, Untch M, Pihan A, et al. Association of urokinase-type plasminogen activator and its inhibitor with disease progression and prognosis in ovarian cancer. Clin Cancer Res 2001;7:1743-9.
7. Matsuzaki H, Kobayashi H, Yagyu T, et al. Plasma bikunin as a favorable prognostic factor in ovarian cancer. J Clin Oncol 2005;23:1463-72.
8. Nielsen JS, Jakobsen E, Holund B, et al. Prognostic significance of p53, Her-2, and EGFR overexpression in borderline and epithelial ovarian cancer. Int J Gynecol Cancer 2004;14:1086-96.
9. Spentzos D, Levine DA, Ramoni MF, et al. Gene expression signature with independent prognostic significance in epithelial ovarian cancer. J Clin Oncol 2004;22:4700-10.
10. Diamandis EP, Yousef GM, Clements J, et al. New nomenclature for the human tissue kallikrein gene family. Clin Chem 2000;46:1855-8.
11. Yousef GM, Diamandis EP. The new human tissue kallikrein gene family: structure, function, and association to disease. Endocr Rev 2001;22:184-204.
12. Borgono CA, Michael IP, Diamandis EP. Human tissue kallikreins: physiologic roles and applications in cancer. Mol Cancer Res 2004;2:257-80.
13. Diamandis EP. Prostate-specific antigen-its usefulness in clinical medicine. Trends Endocrinol Metab 1998;9:310-6.
14. Diamandis EP, Yousef GM. Human tissue kallikreins: a family of new cancer biomarkers. Clin Chem 2002;48:1198-205.
15. Borgono CA, Diamandis EP. The emerging roles of human tissue kallikreins in cancer. Nat Rev Cancer 2004;4:876-90.
16. Shvartsman HS, Lu KH, Lee J, et al. Overexpression of kallikrein 10 in epithelial ovarian carcinomas. Gynecol Oncol 2003;90:44-50.
17. Welsh JB, Sapinoso LM, Kern SG, et al. Large-scale delineation of secreted protein biomarkers overexpressed in cancer tissue and serum. Proc Natl Acad Sci U S A 2003;100:3410-5.
18. Adib TR, Henderson S, Perrett C, et al. Predicting biomarkers for ovarian cancer using gene-expression microarrays. Br J Cancer 2004;90:686-92.
19. Hibbs K, Skubitz KM, Pambuccian SE, et al. Differential gene expression in ovarian carcinoma: identification of potential biomarkers. Am J Pathol 2004;165:397-414.
20. Gilks CB, Vanderhyden BC, Zhu S, et al. Distinction between serous tumors of low malignant potential and serous carcinomas based on global mRNA expression profiling. Gynecol Oncol 2005;96:684-94.
21. Santin AD, Zhan F, Bellone S, et al. Gene expression profiles in primary ovarian serous papillary tumors and normal ovarian epithelium: identification of candidate molecular markers for ovarian cancer diagnosis and therapy. Int J Cancer 2004;112:14-25.
22. Yousef GM, Polymeris ME, Grass L, et al. Human kallikrein 5: a potential novel serum biomarker for breast and ovarian cancer. Cancer Res 2003;63:3958-65.
23. Diamandis EP, Scorilas A, Fracchioli S, et al. Human Kallikrein 6 (hK6): A new potential serum biomarker for diagnosis and prognosis of ovarian carcinoma. J Clin Oncol 2003;21:1035-43.
24. Kishi T, Grass L, Soosaipillai A, et al. Human kallikrein 8, a novel biomarker for ovarian carcinoma. Cancer Res 2003;63:2771-4.
25. Luo LY, Katsaros D, Scorilas A, et al. The serum concentration of human kallikrein 10 represents a novel biomarker for ovarian cancer diagnosis and prognosis. Cancer Res 2003;63:807-11.
26. Diamandis EP, Okui A, Mitsui S, et al. Human Kallikrein 11: A new biomarker of prostate and ovarian carcinoma. Cancer Res 2002;62:295-300.
27. Borgono CA, Grass L, Soosaipillai A, et al. Human kallikrein 14: a new potential biomarker for ovarian and breast cancer. Cancer Res 2003;63:9032-41.
28. Yoshida S, Taniguchi M, Hirata A, et al. Sequence analysis and expression of human neuropsin cDNA and gene. Gene 1998;213:9-16.
29. Chen ZL, Yoshida S, Kato K, et al. Expression and activity-dependent changes of a novel limbic-serine protease gene in the hippocampus. J Neurosci 1995;15:5088-97.
30. Okabe A, Momota Y, Yoshida S, et al. Kindling induces neuropsin mRNA in the mouse brain. Brain Res 1996;728:116-20.
31. Momota Y, Yoshida S, Ito J, et al. Blockade of neuropsin, a serine protease, ameliorates kindling epilepsy. Eur J Neurosci 1998;10:760-4.
32. Komai S, Matsuyama T, Matsumoto K, et al. Neuropsin regulates an early phase of schaffer-collateral long-term potentiation in the murine hippocampus. Eur J Neurosci 2000;12:1479-86.
33. Mitsui S, Tsuruoka N, Yamashiro K, et al. A novel form of human neuropsin, a brain-related serine protease, is generated by alternative splicing and is expressed preferentially in human adult brain. Eur J Biochem 1999;260:627-34.
34. Shimizu-Okabe C, Yousef GM, Diamandis EP, et al. Expression of the kallikrein gene family in normal and Alzheimer's disease brain. Neuroreport 2001;12:2747-51.
35. Kishi T, Grass L, Soosaipillai A, et al. Human kallikrein 8: immunoassay development and identification in tissue extracts and biological fluids. Clin Chem 2003;49:87-96.
36. Yousef GM, Polymeris ME, Yacoub GM, et al. Parallel overexpression of seven kallikrein genes in ovarian cancer. Cancer Res 2003;63:2223-7.
37. Underwood LJ, Tanimoto H, Wang Y, et al. Cloning of tumor-associated differentially expressed gene-14, a novel serine protease overexpressed by ovarian carcinoma. Cancer Res 1999;59:4435-9.
38. Magklara A, Scorilas A, Katsaros D, et al. The human KLK8 (neuropsin/ovasin) gene: identification of two novel splice variants and its prognostic value in ovarian cancer. Clin Cancer Res 2001;7:806-11.
39. Shigemasa K, Tian X, Gu L, et al. Human kallikrein 8 (hK8/TADG-14) expression is associated with an early clinical stage and favorable prognosis in ovarian cancer. Oncol Rep 2004;11:1153-9.
40. Pettersson F. Annual report on the treatment in gynecological cancer. Stockholm: International Federation of Gynecology and Obstetrics: 1994. p. 83-102.
41. Day TG, Jr., Gallager HS, Rutledge FN. Epithelial carcinoma of the ovary: prognostic importance of histologic grade. J Natl Cancer Inst Monogr 1975;42:15-21.
42. Serov SF, Sorbin LH. Histological typing of ovarian tumors. World Health Organization: 1973.
43. Cox DR. Regression models and life tables. J R Stat Soc B 1972;34:187-202.
44. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
45. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966;50:163-70.
46. Duffy MJ. Proteases as prognostic markers in cancer. Clin Cancer Res 1996;2:613-8.
47. Tanimoto H, Shigemasa K, Tian X, et al. Transmembrane serine protease TADG-15 (ST14/Matriptase/MT-SP1): expression and prognostic value in ovarian cancer. Br J Cancer 2005;92:278-83.
48. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002;2:161-74.
49. Shimizu C, Yoshida S, Shibata M, et al. Characterization of recombinant and brain neuropsin, a plasticity-related serine protease. J Biol Chem 1998;273:11189-96.
50. Lee P, Rosen DG, Zhu C, et al. Expression of progesterone receptor is a favorable prognostic marker in ovarian cancer. Gynecol Oncol 2005;96:671-7.
51. Meyer T, Rustin GJ. Role of tumor markers in monitoring epithelial ovarian cancer. Br J Cancer 2000;82:1535-8.
52. Cane S, Bignotti E, Bellone S, et al. The novel serine protease tumor-associated differentially expressed gene-14 (KLK8/Neuropsin/Ovasin) is highly overexpressed in cervical cancer. Am J Obstet Gynecol 2004;190:60-6.